IL22RA1 and breast carcinoma: In comparison, the overall survival curves indicated that the IL-22R1 signature is not associated with poor survival outcomes in breast cancer patients, although cases with an elevated expression of S1PR1 exhibited a lower overall survival rate (p = 0.016, Figure S4).